Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

 - If approved by the European Commission, patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia, for whom hematopoietic stem cell...

Related Keywords

United States ,London ,City Of ,United Kingdom ,Australia ,Saudi Arabia ,Boston ,Massachusetts ,Rome ,Lazio ,Italy ,America ,Saudi ,Great Britain ,Franco Locatelli ,European Union ,Exchange Commission ,Linkedin ,Catholic University Of The Sacred Heart ,Companies To Work ,Committee For Medicinal Products Human Use ,European Medicines Agency ,Drug Authority ,Youtube ,Vertex Pharmaceuticals Incorporated Nasdaq ,Department Of Pediatric Hematology ,Drug Administration ,Instagram ,Regulatory Agency ,European Commission ,Facebook ,Vertex Pharmaceuticals Incorporated ,Medicinal Products ,Human Use ,Nia Tatsis ,Executive Vice President ,Chief Regulatory ,Quality Officer ,Catholic University ,Sacred Heart ,Pediatric Hematology ,Bambino Ges ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Saudi Food ,Conditional Marketing Authorizations ,Prescribing Information ,Patient Information ,North America ,Top Employers ,Private Securities Litigation Reform Act ,Markets ,